Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Robert Delaune (NPI 1497723514)

Field	Value
Entity Type	Individual
Organization	Robert Delaune
Address	1580 Beam Ave
City	Maplewood
State	MN
ZIP	55109
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 14, 2006

Payer Source	Total Paid
Medicare	$1.9M
Medicaid	$0

Key Findings

ROBERT DELAUNE’s Medicare billing is heavily oncology infusion–centric: the top Medicare revenue drivers are J9271 (pembrolizumab) with $941.6K revenue and 21.4K claims, J9299 (nivolumab) with $248.2K revenue and 10.3K claims, and Q5118 (bevacizumab-bvzr biosimilar) with $73.8K revenue and 3.2K claims. These codes are all infusion or injectable oncology agents, indicating the provider operates a treatment-focused oncology practice that delivers high volumes of immunotherapy and targeted biologic infusions rather than primarily procedural or surgical oncology services.

Revenue concentration is high: the precomputed top-3 Medicare codes account for 70.0% of this provider's total Medicare revenue, with J9271 alone representing 52.1% of Medicare revenue ($941.6K). This degree of concentration implies that overall Medicare revenue performance is strongly tied to utilization and reimbursement trends for a few expensive immunotherapy agents.

Payer mix is effectively single-payer Medicare: lifetime Medicare revenue is $1.9M while Medicaid shows none on file. The absence of Medicaid billing makes this practice highly dependent on Medicare reimbursement and patient populations covered by Medicare.

Competitive standing is mixed across products: for J9271 the provider ranks #328 of 1841 nationally (82th percentile; typical, unremarkable volume for this code), indicating a solid but not dominant national position for pembrolizumab; by contrast J9299 ranks #343 of 505 (32th percentile; typical, unremarkable volume), reflecting a more modest national presence for nivolumab. The biosimilar Q5118 ranks #44 of 161 (73th percentile; typical, unremarkable volume), suggesting relatively stronger uptake of this bevacizumab biosimilar versus many peers.

There are clear statistical outliers in the code mix: J9171 (docetaxel) is an extreme outlier, ranking #2 of 207 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), which signals an unusually high docetaxel administration volume compared with peers. Several other administration and chemotherapy codes are also high versus peers — 96413 ranks in the 93th percentile (notably above typical national volume) and 96375 ranks in the 95th percentile (notably above typical national volume) — underscoring an above-typical procedural throughput for chemotherapy delivery.

The practice shows substantial supportive-care and ancillary service activity consistent with longitudinal oncology management: high claim counts but lower per-claim revenue appear for supportive agents such as J0881 (11.4K claims, $22.7K revenue) and J0185 (21.1K claims, $21.1K revenue), while E/M and lab services (99214: 595 claims, $55.3K; 80053: 911 claims, $9.1K; 85025: 1.1K claims, $8.6K) reflect ongoing patient monitoring and management. This mix suggests office-based management of complex oncology patients with both drug administration and routine monitoring coded alongside high-cost immunotherapies.

Operational scale for infusion services is evident from claim volumes for key drugs and infusion-related codes: J9271 shows 21.4K claims and J9299 shows 10.3K claims, and administration/add-on codes such as 96417 (175 claims, $9.1K) and 96375 (833 claims, $10K) are present at elevated percentiles. These volumes are consistent with a high-throughput infusion clinic or oncology practice model that delivers frequent, repeat biologic and chemotherapy administrations.

Provider tenure is long-standing: the NPI was enumerated 2006-03-14 (~20 years ago), indicating prolonged participation in Medicare. That longevity, combined with concentrated Medicare revenue and no Medicaid activity on file, suggests an established, Medicare-focused oncology practice with a stable operational history.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

71 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	21,400	$40	$941.6K
J9299	Injection, nivolumab, 1 mg	10,340	$20	$248.2K
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	3,210	$20	$73.8K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	890	$80	$71K
J0897	Injection, denosumab, 1 mg	3,600	$20	$68.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	550	$110	$58K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	600	$90	$55.3K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	360	$130	$48.3K
78815	PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.…	30	$1,220	$30.4K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	1,240	$20	$26K

Showing 1–10 of 71

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 71 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Robert Delaune — 13 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

71 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	70	7,200	$40	$323.3K
J9299	5	20	5,240	$20	$159.4K
J0897	18	90	1,770	$20	$50.8K
J2506	3	20	290	$80	$34.3K
Q5118	2	20	990	$20	$33.7K
Q5119	16	30	1,380	$20	$29.5K
78815	127	180	50	$250	$25.6K
J0881	8	20	10,680	$1	$25.4K
A9552	42	60	30	$370	$17.2K
J9217	7	80	80	$130	$17.1K

Showing 1–10 of 71

Related Providers

Other providers that share a Tax Identification Number (TIN) with Robert Delaune, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Holland Center	MN	Developmentally Disabled Services Day Training Agency	$0	$16.3M
Minnesota Oncology Hematology, PA	MN	Hematology & Oncology Physician	$0	$8.1M
Vladimir Hugec	MN	Hematology & Oncology Physician	$1.8M	$0
Yang Liu	MN	Hematology & Oncology Physician	$1.4M	$0
David King	MN	Medical Oncology Physician	$1.3M	$0
Avina Singh	MN	Hematology & Oncology Physician	$971.9K	$0
Ben Zhang	MN	Hematology & Oncology Physician	$914.4K	$0
Uzma Ali	MN	Hematology & Oncology Physician	$868.9K	$0
Samith Thomas Kochuparambil	MN	Hematology & Oncology Physician	$827.8K	$0
Ryan Funk	MN	Radiation Oncology Physician	$716.7K	$0

Nearby Providers

Other providers in the same ZIP code as Robert Delaune, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Rem Ramsey, Inc.	MN	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$207.6M
Community Dental Care Inc	MN	General Practice Dentistry	$0	$30.7M
Senior Home Living Inc	MN	Personal Care Attendant	$0	$29.4M
Rainbow Home Healthcare Inc	MN	Home Health Agency	$0	$22.2M
Healtheast St. John's Hospital	MN	General Acute Care Hospital	$0	$17.9M
Cochran Recovery Services	MN	Substance Abuse Rehabilitation Facility	$0	$15.4M
Ardent Home Health Care Inc.	MN	Home Health Agency	$0	$12.2M
First Nations, LLC	MN	In Home Supportive Care Agency	$0	$11.3M
Hmong Minnesota Senior Center	MN	Adult Day Care Clinic/Center	$0	$10M
Healtheast Medical Research Institute	MN	Clinic/Center	$0	$7.4M

Robert Delaune — Billing Profile & Reimbursement Data

Sign up for Robert Delaune — Billing Profile & Reimbursement Data policy alerts

Robert Delaune — Billing Profile & Reimbursement Data

Sign up for Robert Delaune — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References